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Polyunsaturated Fatty
Acids in Heart Failure
Should We Give More
and Give Earlier?*
W. H. Wilson Tang, MD, Michael A. Samara, MD
Cleveland, Ohio
There is an emerging paradox that confronts the care for
patients with heart failure. On the one hand is the well-
chronicled, woeful underutilization of evidence-based,
guideline-supported therapies (1). On the other hand is the
growing recognition that a monolithic approach to this very
complex and heterogeneous disease is suboptimal. While we
strive to fulfill performance measures, we simultaneously
aspire to refine and individualize patient care and demand
“evidence” to target new treatments to the subset of patients
who will benefit most. It is with this background and with
a decade-long drought in new drug therapies for heart
See page 870
failure that the story of n-3 polyunsaturated fatty acids
(PUFAs) in heart failure prevention and treatment has
unfolded. Over the last 3 decades, an extensive body of
observational, experimental, and now randomized clinical
trial data has built upon the initial observations of Bang and
Dyeberg (2) to present a compelling storyline for the
benefits of n-3 PUFAs in cardiovascular disease, particu-
larly eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA). Animal and human studies have provided
insights into the mechanisms by which these benefits may
be achieved, including improvements in blood pressure
and systemic vascular resistance, autonomic function,
cardiac relaxation and filling, ventricular remodeling,
arrhythmic risk, coagulation and thrombosis, and inflam-
mation (Fig. 1) (3,4).
In 1999, the GISSI (Gruppo Italiano per lo Studio della
Sopravvivenza nell’Infarto Miocardico) Prevenzione trial
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reported that he has no relationships to disclose.represented the culmination of an extensive body of litera-
ture showing a 10% to 20% reduction in fatal and nonfatal
cardiovascular end points in patients receiving moderate
doses of n-3 PUFAs. The trial demonstrated a 21% relative
risk reduction in death among patients taking 1 g of n-3
PUFAs (containing 850 to 882 mg of EPA/DHA ethyl
esters with a ratio of 1:1.2) after myocardial infarction. This
was achieved principally due to a reduction in sudden cardiac
death (5). Post hoc subgroup analysis revealed that this
reduction in sudden cardiac death was concentrated in patients
with systolic dysfunction (relative risk: of 0.42 [95% confidence
interval: 0.26 to 0.67]), and was in fact nonsignificant in
patients with left ventricular ejection fraction 50% (6).
Beyond their use in the treatment of known cardiovas-
ular disease, the last decade has seen a series of large
pidemiological studies providing evidence for the effective-
ess of n-3 PUFAs in preventing the development of heart
ailure. During 12 years of follow-up, the Cardiovascular
ealth Study demonstrated that among 4,738 elderly sub-
ects, consumption of baked/broiled fish or supplemental
-3 PUFAs conferred a lower risk of incident heart failure
7). This risk was inversely proportional to the quantity of
sh/supplement intake with a 32% relative risk reduction in
atients consuming the equivalent of 1 g/day of n-3
UFA, and the trend across consumption categories
chieved statistical significance (7). In contrast, patients
onsuming much lower quantities of fish (the equivalent of
8 to 313 mg/day of n-3 PUFAs) in the Rotterdam study
ad no significant risk reduction (8). The large JACC
Japan Collaborative Cohort) study reaffirmed the inverse
elationship between fish and supplemental n-3 PUFA
ntake and heart failure–associated mortality, although the
rend only achieved statistical significance in patients taking
upplemental n-3 PUFA (9). These results were further
orroborated by data from the ARIC (Atherosclerosis Risk
n Community) study, which demonstrated that higher
lasma levels of DHA were associated with a lower risk for
eveloping heart failure in women (10).
Cumulatively, these findings contributed to the hypoth-
sis that n-3 PUFA supplementation in relatively high doses
ould result in reductions in heart failure–associated mor-
idity and mortality in patients with established heart failure
f any etiology, and that these effects would be largely driven
y reductions in nonfatal arrhythmic complications and
udden cardiac death as in GISSI-Prevenzione. To investi-
ate this hypothesis, the GISSI-HF trial enrolled nearly
,000 patients with New York Heart Association (NYHA)
unctional class II to IV heart failure and randomized them
o 1 g/day of n-3 PUFA versus placebo on top of optimal
edical care. Over the 3.9-year median follow-up, n-3
UFA use resulted in a modest 9% relative risk reduction in
ll-cause mortality and an 8% reduction in the composite of
ortality and cardiovascular hospitalization (11). Surpris-
ngly, these benefits were conferred without a reduction in
udden cardiac death, hospitalizations for heart failure, or
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small but significant improvement in left ventricular ejection
fraction with n-3 PUFA but not with rosuvastatin (12).
Although providing the strongest evidence to date for the
role for n-3 PUFA in established heart failure, GISSI-HF
managed to generate as many questions as it answered. How
were these benefits achieved? Why was the risk reduction so
small compared with that anticipated by prior data? Which
patients with heart failure benefit most? Was the n-3 PUFA
dose insufficient? The desire to answer these questions and
the lack of a second large confirmatory trial have clearly
contributed to the ambivalence towards adopting n-3
PUFA use in the broader heart failure population and
incorporating the recommendation into current guidelines.
In this issue of the Journal, Nodari et al. (13) report
esults from a mechanistic study of 133 subjects examining
he effect of n-3 PUFA therapy on conventional measures of
ystolic and diastolic dysfunction, ventricular remodeling,
nd functional impairment. Although not a prespecified end
oint with relatively small event rates, the marked reduction
n cardiovascular and heart failure hospitalizations in the
urrent study stand in stark contrast to the modest reduction
resent in GISSI-HF. Although patients in both studies
ere generally on optimal medical therapy, several contrasts
Figure 1 Beneficial Effects of n-3 PUFAs in Heart Failure
AA  arachadonic acid; COX  cyclooxygenase; DHA  docosahexaenoic acid; EP
IL  interleukin; NF-KB  nuclear factor kappa B; NO  nitric oxide; PAF  platele
systolic blood pressure; SVR  systemic vascular resistance; TNF  tumor necros
polyunsaturated fatty acids.etween this study and GISSI-HF are illustrative. First, thisstudy was confined to patients with angiographically proven
nonischemic cardiomyopathy as compared with patients in
GISSI-HF who may have had heart failure from any
etiology. Furthermore, in contrast to GISSI-HF, this study
focused on a patient population with less advanced heart
failure, having a mean left ventricular ejection fraction of
37% (vs. 33% in GISSI-HF), NYHA functional class I to II
symptoms (vs. approximately 40% of patients with NYHA
functional class III or IV symptoms in GISSI-HF), and no
deaths during the 12 months of follow-up. Pre-defined
subgroup analysis from GISSI-HF suggested a stronger
trend favoring n-3 PUFA use in patients with NYHA
functional class II symptoms as compared with those with
NYHA functional class III to IV symptoms (hazard ratio:
0.93, 95% confidence interval: 0.86 to 1.01) (11). Analo-
gously in the current study, multivariate analysis demon-
strated that a shorter duration of heart failure predicted
subsequent improvements in left ventricular ejection frac-
tion. Finally, one-half of the patients enrolled in GISSI-HF
experienced a heart failure hospitalization within the previ-
ous year, alluding to their overall poorer prognosis (14).
That being said, almost 1 out of 5 subjects in this study still
experienced a heart failure hospitalization within a year.
Cumulatively, the previously demonstrated marked benefits
icosapentaenoic acid; ET  endothelin; ICAM  intracellular adhesion molecule;
ating factor; PPAR  peroxisome proliferator-activated receptor gamma; SBP 
tor; TxA2  thromboxane A2; VCAM  vascular cell adhesion molecule; PUFA A  e
t activ
is facobserved in the primary prevention of heart failure and the
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that n-3 PUFAs are most effective when introduced early in
the course of cardiomyopathy, when they may potentially
exert their effects on viable myocardium. This type of
divergent effect across the spectrum of heart failure has been
proposed for other drugs such as statins (15), and should
n-3 PUFA therapy be considered, they should be given
prior to advanced stages of heart failure.
Another significant difference is the fact that subjects in
the current study were given higher doses of n-3 PUFAs
(5 g of EHA/DPA daily for a month and 2 g for the
remainder of the study) than those given in GISSI-HF
(1 g of EHA/DPA). On the basis of the lack of any
subject withdrawal and the high level of compliance as
assessed by pill counting, this formulation of n-3 PUFA
appears well tolerated. Answering the question of whether
or not higher or “pulse” doses of n-3 PUFAs can achieve
more favorable clinical and echocardiographic outcomes
reaffirms the importance of phase II, dose-ranging studies in
heart failure clinical trial programs. This is a critical ques-
tion to address, since prescription-strength, high-dose n-3
PUFA regimens differ significantly, from the lower and
inconsistent dosages found in over-the-counter supplements
(some have 300 mg or less EHA/DPA per pill). In other
words, simply telling patients to take “fish oil” supplements
without understanding the adequacy of dosing is unlikely to
yield the same benefits as promised in the current study.
One final provocative finding in the current study is the
marked reduction in inflammatory cytokines achieved with
the study regimen and the fact that multivariate analysis
established higher baseline values of tumor necrosis factor
(TNF)-alpha as a predictor of improvement in left ventric-
ular ejection fraction. This finding is consistent with the
post hoc analysis of data from GISSI-HF, which has
demonstrated that circulating levels of the TNF receptor
osteoprotegerin were strongly associated with the incidence
of death and the composite end point of death and heart
failure hospitalization (16). Whether exerting this immune-
modulating effect earlier in the course of disease (as previ-
ously demonstrated in animal studies) impacts disease pro-
gression remains to be seen. Regardless, these data may
suggest a potential role for the use of “inflammatory
biomarkers” in selecting patients for n-3 PUFA therapy and
for serving as potential biomarkers to gauge drug response.
That being said, reliable inflammatory biomarkers are few
and far between in the clinical setting (in fact, none of the
cytokines measured are available for routine testing), and high
cytokine levels are often generated in those with more ad-
vanced disease states. Defining this window of opportunity for
n-3 PUFA therapy to exert its maximal effect on the natural
history of heart failure is worthy of further investigation.
We continue to strive for the best supportive evidence for
our treatment approaches. However in the era of personal-
ized medicine, traditional large-scale clinical trials that have
revolutionized heart failure care are unlikely to be the lone
means to this end. With their concomitant need for largesample sizes and high-risk patients to achieve adequate
event rates, these trial designs may be particularly inept at
informing the management of specific groups of less ad-
vanced patients. This study succeeds in demonstrating how
a modest treatment effect observed in a broad, unselected
heart failure population can be magnified when applied to a
smaller but enriched population of heart failure patients.
With the fortunate hindsight of GISSI-HF, Nodari et al.
(13) present a compelling test case for the dilemma facing
clinicians and guideline committees alike. Would the ben-
efits be more apparent if n-3 PUFA supplementation was
given at higher doses and at earlier disease stages than that
in GISSI-HF? Without a new clinical trial in sight, we are
now challenged to ask ourselves whether we can be con-
vinced to prescribe an otherwise safe and well-tolerated (but
not inexpensive) drug to a broad heart failure population
without the traditional strength of endorsement that large-
scale pivotal studies provide, or whether future clinical
effectiveness studies are needed to justify such indications.
The story for n-3 PUFAs in heart failure is still being
written, but it is not too early to begin to heed its lessons.
Among these is the importance of opening the door for
future trials in metabolic interventions to patients who are
not too late in the course of their disease to benefit from
what are otherwise “preventive” therapies.
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